Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall
about
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patientsThe HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyTrastuzumab containing regimens for early breast cancerNeoadjuvant nab-paclitaxel in the treatment of breast cancerBrain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentCurrent therapeutic strategies of anti-HER2 treatment in advanced breast cancer patientsNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerNewer therapies for the treatment of metastatic breast cancer: a clinical updateNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerInflammatory breast cancer: New factors contribute to disease etiology: A reviewInflammatory breast cancer: what we know and what we need to learnBreast cancer chemoprevention: old and new approachesNeoadjuvant therapy in the treatment of breast cancerLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsTwenty years of anti-HER2 therapy-associated cardiotoxicityRole of positron emission tomography for the monitoring of response to therapy in breast cancerTreatment of early-stage HER2+ breast cancer-an evolving fieldPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerMeta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer paPertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with TrastuzumabPreoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.Trial watch: Immunostimulatory cytokines in cancer therapy.
P2860
Q21261244-EC095490-FEEC-407A-B9CE-E7525A67103FQ21284978-35828B75-EC33-486B-9AC3-9A11C4BB7E46Q24200192-4370BC6A-0CAC-4166-B04E-9D9B369C4C8CQ26748822-2F5237A5-8818-4842-971F-A261FF8F71F4Q26751008-7BBD667E-BA9B-4673-86F2-1CC8294FEE0BQ26752024-02938D6A-4761-4005-A470-C717C26F2191Q26764879-E546F833-413A-42CC-A19F-729E301D4250Q26785612-2E166EC4-B653-43A6-817B-45AB3DC69EC6Q26865260-199DA9AD-36C7-49DF-9BD4-409788F0F7CAQ27001729-ED96C73E-48C4-4E0E-B1D0-BB20FAF9830FQ27025863-00CB152D-A3AC-4DAA-852C-68DDE6B3AFE4Q27027856-37CDF5D7-011B-4A4D-96CB-0117EE833397Q27028128-AAC9BB1E-2C37-4A7A-85D3-03C0E2022564Q27693259-15C68770-E20C-477F-AE69-A998AA30A08CQ27694514-DEDEBEF1-E464-48F1-AD6D-1046647E8925Q27851705-D07B6FAE-707E-49AE-BEC1-CADB508498ABQ28067145-CB00C522-1966-45CB-8131-175C10996955Q28072897-2B773EF8-5429-45B3-A603-1122AF069638Q28075322-C8670640-F7AC-4B9A-A885-4CAA60340F38Q28079391-A0E28F81-2639-456D-BFDA-3F4D8DF0F1F7Q28080621-14F71E27-E30C-4B77-A555-B6A6BCE6DBE0Q28081124-1AB3A5E7-3233-4B9A-8814-2781E821912AQ28291395-4E954726-D9F2-4982-B4BB-16832401099BQ28543647-6940C4EB-13B3-4D15-89B5-CDBCB90DEE4DQ30249335-525A5DD0-5C10-429A-90AE-3BA4B403F781Q30318240-FABC8599-F314-48F8-BDB1-CA0997DFAA86Q30371966-060ABE5C-615A-425D-9776-ED46DDC94989Q30661022-F905406B-8295-40C9-B8F4-BC3B59F37C77Q31160308-3234DB13-0824-488A-8C20-9BE3634B80F5Q33364587-42B91FC0-BA7C-49E1-B1B2-2EB570571432Q33407805-0E89AA59-AAE2-40C2-819B-46244BD4AA3CQ33430463-09359683-C2B3-4DEC-98E7-FB201C8C7C1FQ33599465-82CB5F2B-9C48-470B-903A-4FEF2CCE1BD5Q33601653-C42CE960-DF74-4CD2-A4D8-23EAA06E97F2Q33680890-F81F916A-654E-42DA-BF87-B9CA9820F2BEQ33698446-E3791FE0-F03D-4240-8FB4-913D7BA2737FQ33739253-0348A9E2-9751-4C1E-ACA4-EDEB34BA2AD9Q33843810-85F2B19F-F291-46B2-8DA5-BC0D091039B3Q33844469-4BA50145-3FCC-4651-816C-EC27B241284EQ33880165-CC38DCCA-96DC-4AD2-8DF6-D6518C3C1059
P2860
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@en
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@nl
type
label
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@en
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@nl
prefLabel
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@en
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@nl
P2093
P1433
P1476
Neoadjuvant chemotherapy with ...... uperiority trial with a parall
@en
P2093
Alexey Manikhas
Alla Bozhok
Andrea Feyereislova
Belén Ojeda
Claire Barton
Eva Ciruelos
Federico Vazquez
Luca Gianni
Mauro Mansutti
P304
P356
10.1016/S0140-6736(09)61964-4
P407
P577
2010-01-01T00:00:00Z